What does Cellaïon do?

Cellaïon is a healthcare practice in Mont-Saint-Guibert. Public Limited, started on 2 March 2021, 1 establishment.

What is the address of Cellaïon?

The registered office of Cellaïon is located at Rue Granbonpré 11, 1435 Mont-Saint-Guibert.

Is Cellaïon still active?

Not as usual. The CBE lists Cellaïon with legal situation “Vrijwillige ontbinding – vereffening”.

Is Cellaïon registered on Peppol?

Yes, Cellaïon is registered on the Peppol network with ID 0208:0764522425.

What is the enterprise number of Cellaïon?

The enterprise number of Cellaïon is BE0764522425.

When was Cellaïon founded?

Cellaïon was founded on 2 March 2021.

Who are the directors of Cellaïon?

According to the 2025 annual accounts, the directors of Cellaïon are: Cédric ALTER.

Is Cellaïon a reliable company?

Databakkes does not pass judgement; this is what the sources say: Vrijwillige ontbinding – vereffening according to the CBE, started on 2 March 2021; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Cellaïon make in 2025?

Cellaïon recorded a loss after taxes of € 15,747 in financial year 2025.

What is the revenue of Cellaïon?

As a small company, Cellaïon is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -25,151.

How much does an employee at Cellaïon earn?

The average wage cost per full-time employee at Cellaïon was € 220,000 in 2024: staff costs of € 3.4 million for 15.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Cellaïon have?

According to the 2025 annual accounts, Cellaïon has 0 full-time equivalents (FTE).

Cellaïon (Public Limited) - Mont-Saint-Guibert

Dossier Cellaïon, printed on 29 October 2026 from databakkes.be/en/0764522425/cellaion. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 3 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Shrinking team NBB

FTE fell two years in a row, from 25.2 to 0.
Busy address KBO

20 other companies have their registered office at the same address; threshold 10.
Legal situation KBO

Vrijwillige ontbinding – vereffening according to the CBE.

Financials

Financial year 2025

Cellaïon from Mont-Saint-Guibert, company number BE0764522425, closed financial year 2025 with a result of € -15,747 after tax. For that financial year Cellaïon recorded a gross margin of € -25,151 and equity of € -13.9 million. Compared with financial year 2024, the result moved from € -7.7 million to € -15,747. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 25, 2026.

What it is worth Caution

€ -13.9 million

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -15,747

▲ 100 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.4 million

▲ 12% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -21 million.

People and assets in 2025

Full-time equivalents

▼ 15.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Debts at end 2025

Bank debt

€ 7.6 million

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 2.5 million

▼ 2% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -6,078,669 Gross margin 2022: € -6,078,669 First fiscal year in the series	€ -6,590,813 Gross margin 2023: € -6,590,813 ▼ € 512,144 vs 2022 (€ -6,078,669) Unfavourable step	€ -4,029,044 Gross margin 2024: € -4,029,044 ▲ € 2.6 million vs 2023 (€ -6,590,813) Favourable step	€ -25,151 Gross margin 2025: € -25,151 ▲ € 4 million vs 2024 (€ -4,029,044) Favourable step	▲ € 4 million
Profit after taxes	€ -9,394,008 Profit after taxes 2022: € -9,394,008 First fiscal year in the series	€ -13,234,046 Profit after taxes 2023: € -13,234,046 ▼ € 3.8 million vs 2022 (€ -9,394,008) Unfavourable step	€ -7,708,289 Profit after taxes 2024: € -7,708,289 ▲ € 5.5 million vs 2023 (€ -13,234,046) Favourable step	€ -15,747 Profit after taxes 2025: € -15,747 ▲ € 7.7 million vs 2024 (€ -7,708,289) Favourable step	▲ € 7.7 million
Equity	€ 1,048,079 Equity 2022: € 1,048,079 First fiscal year in the series	€ -6,142,063 Equity 2023: € -6,142,063 ▼ € 7.2 million vs 2022 (€ 1,048,079) Unfavourable step	€ -13,847,585 Equity 2024: € -13,847,585 ▼ € 7.7 million vs 2023 (€ -6,142,063) Unfavourable step	€ -13,863,332 Equity 2025: € -13,863,332 Unchanged (€ -13,847,585) Unfavourable step
Total debts	€ 10,876,108 Total debts 2022: € 10,876,108 First fiscal year in the series	€ 11,558,280 Total debts 2023: € 11,558,280 ▲ 6% vs 2022 (€ 10,876,108) Unfavourable step	€ 15,102,118 Total debts 2024: € 15,102,118 ▲ 31% vs 2023 (€ 11,558,280) Unfavourable step	€ 15,059,896 Total debts 2025: € 15,059,896 Unchanged (€ 15,102,118) Favourable step
Cash	€ 8,298,056 Cash 2022: € 8,298,056 First fiscal year in the series	€ 2,883,660 Cash 2023: € 2,883,660 ▼ 65% vs 2022 (€ 8,298,056) Unfavourable step	€ 1,248,036 Cash 2024: € 1,248,036 ▼ 57% vs 2023 (€ 2,883,660) Unfavourable step	€ 1,393,596 Cash 2025: € 1,393,596 ▲ 12% vs 2024 (€ 1,248,036) Favourable step	▲ 12%
Retained profit	€ -15,038,521 Retained profit 2022: € -15,038,521 First fiscal year in the series	€ -13,234,046 Retained profit 2023: € -13,234,046 ▲ € 1.8 million vs 2022 (€ -15,038,521) Favourable step	€ -20,942,335 Retained profit 2024: € -20,942,335 ▼ € 7.7 million vs 2023 (€ -13,234,046) Unfavourable step	€ -20,958,082 Retained profit 2025: € -20,958,082 Unchanged (€ -20,942,335) Unfavourable step
Bank debt	€ 3,575,000 Bank debt 2022: € 3,575,000 First fiscal year in the series	€ 3,500,000 Bank debt 2023: € 3,500,000 ▼ 2% vs 2022 (€ 3,575,000) Favourable step	€ 7,612,642 Bank debt 2024: € 7,612,642 ▲ 118% vs 2023 (€ 3,500,000) Unfavourable step	€ 7,612,642 Bank debt 2025: € 7,612,642 Unchanged (€ 7,612,642) Unchanged
Balance sheet total	€ 12,376,353 Balance sheet total 2022: € 12,376,353 First fiscal year in the series	€ 7,487,085 Balance sheet total 2023: € 7,487,085 ▼ 40% vs 2022 (€ 12,376,353) Unchanged	€ 2,335,377 Balance sheet total 2024: € 2,335,377 ▼ 69% vs 2023 (€ 7,487,085) Unchanged	€ 2,277,408 Balance sheet total 2025: € 2,277,408 ▼ 2% vs 2024 (€ 2,335,377) Unchanged	▼ 2%
Employees (FTE)	23.6 Employees (FTE) 2022: 23.6 First fiscal year in the series	25.2 Employees (FTE) 2023: 25.2 ▲ 1.6 vs 2022 (23.6) Unchanged	15.5 Employees (FTE) 2024: 15.5 ▼ 9.7 vs 2023 (25.2) Unchanged	0 Employees (FTE) 2025: 0 ▼ 15.5 vs 2024 (15.5) Unchanged	▼ 15.5

Key figures of Cellaïon, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Cellaïon?

What happened at Cellaïon in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Cellaïon is active according to the CBE. Legal situation: Vrijwillige ontbinding – vereffening.

Jul 25, 2026 New annual accounts for financial year 2025: loss of € 15,747. Source: NBB ↗
2024 Cédric ALTER became a director. NBB
Mar 2, 2021 New establishment in Mont-Saint-Guibert. KBO
Mar 2, 2021 Start of the company according to the CBE. KBO

In short

From € 9.4 million loss in 2022 to € 15,747 loss in 2025.

Paid € 10,854 in corporate taxes since 2022.

Original PDFs at the National Bank ↗

Management

Newton Biocapital II 16.9%

Wallonie Entreprendre 16.2%

Fund+ 0.9%

SOPARTEC 0.4%

The stake of Newton Biocapital II, Wallonie Entreprendre, Fund+, SOPARTEC comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Cellaïon

Behind Cellaïon is Cédric ALTER. The shares are held by Newton Biocapital II (16.9%), Wallonie Entreprendre (16.2%), Fund+ (0.9%) and SOPARTEC (0.4%).

Directors

According to the 2025 annual accounts

Cédric ALTER

Liquidator

since 2024

Shareholders

Newton Biocapital II

16.9%

Wallonie Entreprendre

16.2%

Fund+

0.9%

SOPARTEC

0.4%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Granbonpré 11

1435 Mont-Saint-Guibert

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.

All companies at this address →

DE SMET AGRO

€ 8.7 million revenue · 2025

DE SMET S.A. - ENGINEERS & CONTRACTORS

€ 31.8 million revenue · 2025

CEDRIC CLAERHOUDT

€ 937,969 gross margin · 2024

Tools4Patient

€ -431,027 gross margin · 2025

NOVADIP BIOSCIENCES

€ 1.6 million gross margin · 2025

+15 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0764.522.425

VAT number

BE 0764.522.425

Registered office

Rue Granbonpré 11, 1435 Mont-Saint-Guibert

Names & denominations

Cellaïon

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Vrijwillige ontbinding – vereffening

Start date

2 March 2021

Peppol

Active · Active since 29 Sept 2026

Contact

promethera.com [email protected]

Activities · NACE

Activiteiten op het gebied van voeding

Overige menselijke gezondheidszorg, n.e.g.

Speur- en ontwikkelingswerk op biotechnologisch gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

Cellaïon

Warning lights

Financials

What happened to Cellaïon?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions